Metformin / Sitagliptin: 6 agencies, 2008–2022
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 14.4 years separate the first record, 6 May 2008 at AWMSG (Wales), from the most recent, 12 Oct 2022 at HAS (France).
SMC (Scotland) changed its position: restricted on 10 May 2010, recommended by 13 Jan 2014.
No assessment is on file from PBAC (Australia) and CIPM (Spain), each among the eight highest-volume agencies here.
The programme is broad: 9 distinct indication wordings are recorded for metformin / sitagliptin by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess metformin / sitagliptin, on 6 May 2008; PHARMAC (New Zealand) did not open a file until 21 Feb 2019 — an unusually long tail of 10.8 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 12 years in total.
Restriction is doing real work here: 4 of 15 decisive outcomes narrowed metformin / sitagliptin to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
5 of the 6 agencies here assessed metformin / sitagliptin more than once, HAS (France) most often at 16 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for metformin / sitagliptin.
The full ledger for metformin / sitagliptin reads 10 recommended, 8 other, 5 not assessed and 4 no benefit, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 12 Oct 2022 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| PHARMAC (New Zealand) | 21 Feb 2019 | Diabetes - Type 2 | PTAC advice: No Formal Recommendation · decision reached | source |
| G-BA (Germany) | 1 Feb 2018 | Komboglyze — benefit assessment §35a | added benefit: not proven | source |
| AWMSG (Wales) | 7 Jan 2014 | In combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise to improve gly… | outside AWMSG criteria | source |
| SMC (Scotland) | 10 Jun 2013 | Adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus inadequately controlled on their maximal… | accepted (restricted) | source |
27 further decisions for metformin / sitagliptin, across 5 agencies, are not shown here. They link to 18 further source documents.
Related molecules
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- liraglutide — same ATC class A10B — Diabetes
- sitagliptin — same ATC class A10B — Diabetes
- tirzepatide — same ATC class A10B — Diabetes
Coverage: 32 decisions for metformin / sitagliptin from 6 agencies, 2008 to 2022. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.